Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Research and development, Scholars Program · Tagged with: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Scholars Program
Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration, biotechnology · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States, US government
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Health Care · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NATO, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States, United States Department of Health and Human Services
Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company’s international sales efforts have resulted in these sales [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Shareholders, U.S. Food and Drug Administration · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine.
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri · Tagged with: Anthrax vaccines, Board of directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, U.S. Food and Drug Administration, United States